CHD1 and prostate cancer: In occurrence with CHD1 deletion (Figure 2C), SPOP mutations define a distinct prostate cancer subtype, characterized by genomic instability, increased AR transcriptional activity, absence of ERG rearrangements, and increased DNA methylation (60, 91, 92, 94).